Citations

Showing 10 of 108135 citations.

Examining Burnout in Interprofessional Intensive Care Unit Clinicians Using Qualitative Analysis
Colbenson, Gretchen A. , Ridgeway, Jennifer L. , Benzo, Roberto P. , Kelm, Diana J. , Ridgeway, Jennifer L

Mayo Clinic

American Journal of Critical Care | September 1, 2021 | Volume: 30 | Issue: 5 | Pages: 391-396

10.4037/ajcc2021423 | PMID 34467381 Get It

Background Health care professionals working in intensive care units report a high degree of burnout, but this topic has not been extensively studied from an interdisciplinary perspective. Objective To characterize experiences of burnout among members of interprofessional intensive care unit teams and identify possible contributing factors. Methods This qualitative study involved interviews of registered nurses, respiratory therapists, physicians, pharmacists, and a personal care assistant working in multiple intensive care units of a single academic medical center to assess work stressors. Results Team composition was a factor in burnout, particularly when nonphysician team members felt that their opinions were not valued despite the institution’s emphasis on a multidisciplinary team-based model of care. This was especially true when roles were not well defined at the outset of a code situation. Members of nearly all disciplines stated that there was not enough time in a day to complete all the required tasks. Conclusions Multiple factors contribute to work-related stress and burnout across different professions in the intensive care unit. Improved communication and increased receptivity to diverse opinions among members of the multidisciplinary team may help reduce stress.
Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System
Lacy, Brian E. , Moshiree, Baha , Kassebaum, Amy, Abel, Jessica L. , Hanlon, Jennifer, Bartolini, Wilmin , Boinpally, Ramesh , Bochenek, Wieslaw, Fox, Susan M., Mallick, Madhuja, Tripp, Ken, Omniewski, Nicholas, Shea, Elizabeth P., Borgstein, Niels, Chang, Lin

Mayo Clinic

American Journal of Gastroenterology | September 1, 2021 | Volume: 116 | Issue: 9 | Pages: 1929-1937

10.14309/ajg.0000000000001334 | PMID 34465695 Get It

INTRODUCTION: Linaclotide improves abdominal pain and constipation in patients with constipation-predominant irritable bowel syndrome (IBS-C). Patients report additional bothersome abdominal symptoms of bloating and discomfort. The intention of this study was to evaluate linaclotide's efficacy in relieving IBS-C-related abdominal symptoms (bloating, discomfort, and pain) using a novel multi-item Abdominal Score (AS). METHODS: Patients with IBS-C with abdominal pain ≥3 (0–10 scale) were randomized to linaclotide 290 μg or placebo daily for 12 weeks. The AS, derived from the Diary for IBS Symptoms-Constipation, is the average of abdominal bloating, discomfort, and pain at their worst (0 = none, 10 = worst possible). The primary end point was overall change from baseline (CFB) in AS. Secondary end points included CFB in 12-week AS evaluated using cumulative distribution function and 6-week/12-week AS responder (AS improvement ≥2 points for ≥6-week/12-week). RESULTS: Overall, 614 patients (mean age 46.7 years; 81% female) were randomized. All prespecified end points showed significant benefit of linaclotide vs placebo. The mean overall CFB AS reduction for linaclotide was −1.9 vs −1.2 for placebo ( P < 0.0001); the 6-week/12-week AS responder rate was 40.5% for linaclotide vs 23.4% for placebo (odds ratio = 2.2 [95% confidence interval, 1.55–3.12; P < 0.0001]). Diarrhea was the most common treatment-emergent adverse event (linaclotide = 4.6%, placebo = 1.6%). DISCUSSION: Linaclotide significantly reduced multiple abdominal symptoms important to patients with IBS-C (bloating, discomfort, and pain) compared with placebo, as measured by a novel multi-item AS. The AS, derived from the Diary for IBS Symptoms-Constipation, should be considered for use in future IBS-C clinical studies to measure clinically meaningful improvements beyond traditional end points.
Voice Therapy According to the Rehabilitation Treatment Specification System: Expert Consensus Ingredients and Targets
Stan, Jarrad H. Van , Barkmeier‐Kraemer, Julie , Doyle, Patricia, Gherson, Shirley , Kelchner, Lisa , Muise, Jason, Petty, Brian , Roy, Nelson , Stemple, Joseph C., Tolejano, Carol Jorgensen, Van Stan, Jarrad H , Roy, Nelson , Whyte, John , Duffy, Joseph R. , Thibeault, Susan L.

Mayo Clinic

American Journal of Speech-Language Pathology | August 31, 2021 | Volume: 30 | Issue: 5 | Pages: 2169-2201

10.1044/2021_ajslp-21-00076 | PMID 34464550 Get It

Purpose Clinical trials have demonstrated that standardized voice treatment programs are effective for some patients, but identifying the unique individual treatment ingredients specifically responsible for observed improvements remains elusive. To address this problem, the authors used a taxonomy of voice therapy, the Rehabilitation Treatment Specification System (RTSS), and a Delphi process to develop the RTSS-Voice (expert consensus categories of measurable and unique voice treatment ingredients and targets). Method Initial targets and ingredients were derived from a taxonomy of voice therapy. Through six Delphi Rounds, 10 vocal rehabilitation experts rated the measurability and uniqueness of individual treatment targets and ingredients. After each round, revisions (guided by the experts' feedback) were finalized among a primary reader (a voice therapy expert) and two external readers (rehabilitation experts outside the field of voice). Consensus was established when the label and definition of an ingredient or target reached a supramajority threshold (≥ 8 of 10 expert agreement). Results Thirty-five target and 19 ingredient categories were agreed to be measurable, unique, and accurate reflections of the rules and terminology of the RTSS. Operational definitions for each category included differences in the way ingredients are delivered and the way individual targets are modified by those ingredients. Conclusions The consensus labels and operationalized ingredients and targets making up the RTSS-Voice have potential to improve voice therapy research, practice, and education/training. The methods used to develop these lists may be useful for other speech, language, and hearing treatment specifications. Supplemental Material https://doi.org/10.23641/asha.15243357
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable
Jensen, Chelsee , Jensen, Chelsee J

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | August 31, 2021 | Volume: 27 | Issue: 9 | Pages: 1321-1324

10.18553/jmcp.2021.27.9.1321 | PMID 34464211 Get It

Envisioning Future Urinary Tract Infection Diagnostics
Patel, Robin , Bard, Jennifer Dien , May, Larissa, Lee, Francesca M, Hayden, Mary K. , Doernberg, Sarah D B, Haake, David A. , Grigoryan, Larissa, Tsalik, Ephraim L. , Hanson, Kimberly E. , Grigoryan, Larissa , Patel, Robin , Hanson, Kimberly , Grigoryan, Larissa , Polage, Christopher R. , Fabre, Valeria , Doernberg, Sarah B. , Trautner, Barbara W.

Mayo Clinic

Clinical Infectious Diseases | August 31, 2021 | Volume: 74 | Issue: 7 | Pages: 1284-1292

10.1093/cid/ciab749 | PMID 34463708 Get It

Abstract Urinary tract infections (UTIs) are among the most common bacterial infections in the United States and are a major driver of antibiotic use, both appropriate and inappropriate, across healthcare settings. Novel UTI diagnostics are a strategy that might enable better UTI treatment. Members of the Antibacterial Resistance Leadership Group Laboratory Center and the Infectious Diseases Society of America Diagnostics Committee convened to envision ideal future UTI diagnostics, with a view towards improving delivery of healthcare, patient outcomes and experiences, and antibiotic use, addressing which types of UTI diagnostics are needed and how companies might approach development of novel UTI diagnostics.
Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences
Garcia, César A. , Bhargav, Adip G. , Brooks, Mieu, Suárez-Meade, Paola , Mondal, Sujan Kumar , Zarco, Natanael , ReFaey, Karim , Jentoft, Mark E. , Middlebrooks, Erik H. , Carrano, Anna , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Mondal, Sujan K, Jentoft, Mark, Carrano, Anna , Guerrero-Cazares, Hugo , Schiapparelli, Paula , Sarabia-Estrada, Rachel , Middlebrooks, Erik H , Zarco, Natanael , ReFaey, Karim , Snuderl, Matija , Sarabia-Estrada, Rachel

Mayo Clinic

Molecular Cancer Therapeutics | August 31, 2021 | Volume: 20 | Issue: 12 | Pages: 2585-2597

10.1158/1535-7163.mct-20-0547 | PMID 34465594 Get It

Abstract Glioblastoma (GBM) is the most common primary brain cancer in adults where tumor cell heterogeneity and sex differences influence clinical outcomes. Here, we functionally characterize three male and three female patient-derived GBM cell lines, identify protumorigenic BTICs, and create novel male and female preclinical models of GBM. Cell lines were evaluated on the following features: proliferation, stemness, migration, tumorigenesis, clinical characteristics, and sensitivity to radiation, TMZ, rhTNFSF10 (rhTRAIL), and rhBMP4. All cell lines were classified as GBM according to epigenetic subtyping, were heterogenous and functionally distinct from one another, and re-capitulated features of the original patient tumor. In establishing male and female preclinical models, it was found that two male-derived GBM cell lines (QNS108 and QNS120) and one female-derived GBM cell line (QNS315) grew at a faster rate in female mice brains. One male-derived GBM cell line (QNS108) decreased survival in female mice in comparison with male mice. However, no survival differences were observed for mice injected with a female-derived cell line (QNS315). In summary, a panel of six GBM patient-derived cell lines were functionally characterized, and it was shown that BTIC lines can be used to construct sex-specific models with differential phenotypes for additional studies.
Global Incidence of Sporadic Vestibular Schwannoma: A Systematic Review
Marinelli, John P. , Beeler, Cynthia, Carlson, Matthew L. , Cayé‐Thomasen, Per , Spear, Samuel A., Erbele, Isaac D. , Chelf, Cynthia , Beeler, Cynthia J, Chelf, Cynthia J

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 31, 2021 | Volume: 167 | Issue: 2 | Pages: 209-214

10.1177/01945998211042006 | PMID 34464224 Get It

ObjectiveUbiquitous throughout the literature and during patient counseling, vestibular schwannoma is often quoted to affect about 1 per 100,000 people. Yet, reports from distinct international populations suggest that the incidence is likely much higher. The objective of the current work was to systematically characterize the global incidence of sporadic vestibular schwannoma.Data SourcesScopus, Embase, and PubMed.Review MethodsPopulation‐based studies reporting incidence rates of sporadic vestibular schwannoma between January 2010 and August 2020 were searched with language restrictions requiring reports to be published in Chinese, English, German, Italian, or Spanish. The protocol was registered with PROSPERO (CRD42021228208) prior to commencement of data collection. PRISMA guidelines for transparent reporting of systematic reviews were followed.ResultsAmong 424 citations, 6 publications covering 4 distinct populations from Denmark, the Netherlands, Taiwan, and the United States met inclusion criteria. Most recent incidence rates of among all ages ranged between 3.0 and 5.2 per 100,000 person‐years. Highest incidence rates were reported among patients aged ≥70 years, peaking at 20.6 per 100,000 person‐years. One study from the United States reported the incidence of asymptomatic, incidentally diagnosed tumors at a rate of 1.3 per 100,000 person‐years from 2012 to 2016.ConclusionsRecent international incidence rates of sporadic vestibular schwannoma exceed the commonly quoted “1 per 100,000” figure by up to 5‐fold among all ages and by up to 20‐fold among age groups at highest risk. Based on modern incidence rates, the lifetime prevalence of developing sporadic vestibular schwannoma likely exceeds 1 per 500 persons.
Association Between SARS-CoV-2 Cycle Threshold Values and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis
Shah, Vishal P. , Farah, Wigdan , Hill, James C. , Hassett, Leslie C. , Binnicker, Matthew J. , Yao, Joseph D. , Farah, Wigdan H, Hassett, Leslie C , Farah, Wigdan , Murad, M. Hassan

Mayo Clinic

Open Forum Infectious Diseases | August 31, 2021 | Volume: 8 | Issue: 9 | Pages: No page available

10.1093/ofid/ofab453 | PMID 34584900 Get It

Abstract Cycle threshold (CT) values are correlated with the amount of viral nucleic acid in a sample and may be obtained from some qualitative real-time polymerase chain reaction tests used for diagnosis of most patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, CT values cannot be directly compared across assays, and they must be interpreted with caution as they are influenced by sample type, timing of sample collection, and assay design. Presently, the correlation between CT values and clinical outcomes is not well understood. We conducted a systematic review and meta-analysis of published studies through April 19, 2021, that reported an association between CT values and hospitalization, disease severity, and mortality in patients ≥18 years old with SARS-CoV-2. A meta-analysis of 7 studies showed no significant difference in mean CT values between hospitalized and nonhospitalized patients. Among hospitalized patients, those with CT values &lt;25 had a high risk of more severe disease and mortality than patients with CT values &gt;30 (odds ratio [OR], 2.31; 95% CI, 1.70 to 3.13; and OR, 2.95; 95% CI, 2.19 to 3.96; respectively). The odds of increased disease severity and mortality were less pronounced in patients with CT values of 25–30 compared with &gt;30.
Intermittent Hypoxia-Hyperoxia and Oxidative Stress in Developing Human Airway Smooth Muscle
Bartman, Colleen M. , Awari, Daniel W. , Prakash, Y. S. , Awari, Daniel Wasim, Prakash, Y S , Bartman, Colleen M , Pabelick, Christina M.

Mayo Clinic

Antioxidants | August 31, 2021 | Volume: 10 | Issue: 9 | Pages: 1400

10.3390/antiox10091400 | PMID 34573032 Get It

Premature infants are frequently and intermittently administered supplemental oxygen during hypoxic episodes, resulting in cycles of intermittent hypoxia and hyperoxia. The relatively hypoxic in utero environment is important for lung development while hyperoxia during the neonatal period is recognized as detrimental towards the development of diseases such as bronchopulmonary dysplasia and bronchial asthma. Understanding early mechanisms that link hypoxic, hyperoxic, and intermittent hypoxic-hyperoxic exposures to altered airway structure and function are key to developing advanced therapeutic approaches in the clinic. Changes in oxygen availability can be detrimental to cellular function and contribute to oxidative damage. Here, we sought to determine the effect of oxygen on mitochondria in human fetal airway smooth muscle cells exposed to either 5% O2, 21% O2, 40% O2, or cycles of 5% and 40% O2 (intermittent hypoxia-hyperoxia). Reactive oxygen species production, altered mitochondrial morphology, and changes in mitochondrial respiration were assessed in the context of the antioxidant N-acetylcysteine. Our findings show developing airway smooth muscle is differentially responsive to hypoxic, hyperoxic, or intermittent hypoxic-hyperoxic exposure in terms of mitochondrial structure and function. Cycling O2 decreased mitochondrial branching and branch length similar to hypoxia and hyperoxia in the presence of antioxidants. Additionally, hypoxia decreased overall mitochondrial respiration while the addition of antioxidants increased respiration in normoxic and O2-cycling conditions. These studies show the necessity of balancing oxidative damage and antioxidant defense systems in the developing airway.
Ultrasound-Guided Percutaneous Ethanol Ablation for Local Regional Recurrence of Medullary Thyroid Cancer
Yamashita, Thomas Szabo , Rogers, Richard T. , Foster, Trenton R. , Lyden, Melanie L. , McKenzie, Travis J. , Thompson, Geoffrey B. , Dy, Benzon M. , Yamashita, Thomas S, Szabo Yamashita, Thomas , Morris, John C.

Mayo Clinic

The American Surgeon™ | August 31, 2021 | Volume: 87 | Issue: 9 | Pages: 1396-1399

10.1177/00031348211041563 | PMID 34461779 Get It